基于生物标志物与临床评分系统的老年脓毒症早期识别策略探索

doi:10.3969/j.issn.1003-9198.2026.01.013

摘要/Abstract

摘要： 脓毒症是危及老年患者的危急重症之一。老年人常因生理储备下降、免疫反应减弱及多病共存等特点,导致急诊科对老年脓毒症的早期识别难度增加。由于老年患者自身特点与脓毒症的交互影响,目前临床常用的诊断工具仍存在一定的局限性。本文对脓毒症相关的新兴检测手段及新技术与多学科方法的研究进展进行综述,为老年脓毒症患者的早期识别提供新的思路。

关键词: 脓毒症, 生物标志物, 老年人, 早期识别

Abstract: Sepsis is one of the critical conditions endangering elderly patients.Due to characteristics such as diminished physiological reserve, weakened immune response, and frequent multimorbidity in the elderly, the early recognition of sepsis in this population within the emergency department becomes more challenging. The mutual influence between these age-specific factors and sepsis itself imposes limitations on currently available clinical diagnostic tools. This article reviews the emerging detection methods and interdisciplinary approaches, to provide new method for early recognition of sepsis in elderly patients.

Key words: sepsis, biomarker, aged, early recognition

中图分类号:

R 459.7

李子千, 秦海东. 基于生物标志物与临床评分系统的老年脓毒症早期识别策略探索[J]. 实用老年医学, 2026, 40(1): 62-66.

LI Ziqian, QIN Haidong. Exploration of an early identification strategy for sepsis in the elderly based on biomarkers and clinical scoring systems[J]. Practical Geriatrics, 2026, 40(1): 62-66.

参考文献

[1] 尚召明, 陈明泉. 老年脓毒症的流行病学特点[J]. 实用老年医学, 2025, 39(4): 325-329.
[2] DONG R, LIU W, WENG L, et al. Temporal trends of sepsis-related mortality in China, 2006—2020: a population-based study[J]. Ann Intensive Care, 2023, 13(1): 71.
[3] WENG L, ZENG X Y, YIN P, et al. Sepsis-related mortality in China: a descriptive analysis[J]. Intensive Care Med, 2018, 44(7): 1071-1080.
[4] WILLIAMS J M, GREENSLADE J H, MCKENZIE J V, et al. Systemic inflammatory response syndrome, quick sequential organ function assessment, and organ dysfunction: insights from a prospective database of ED patients with infection[J]. Chest, 2017, 151(3): 586-596.
[5] 邹浩, 姜东旭, 张琳琳. 慢性病患者就医延迟评估工具及影响因素的研究进展[J]. 中国全科医学, 2022, 25(7): 893-898.
[6] JIANG B, RU X, SUN H, et al. Pre-hospital delay and its associated factors in first-ever stroke registered in communities from three cities in China[J]. Sci Rep, 2016, 6: 29795.
[7] 王萧冉, 关新月, 张丹. 老年共病患者就医延迟行为及其影响因素研究[J]. 中国全科医学, 2024(20): 2505-2511.
[8] SINGER M, DEUTSCHMAN C S, SEYMOUR C W, et al. The third international consensus definitions for sepsis and septic shock (sepsis-3)[J]. JAMA, 2016, 315(8): 801-810.
[9] SEYMOUR C W, LIU V X, IWASHYNA T J, et al. Assessment of clinical criteria for sepsis: for the third international consensus definitions for sepsis and septic shock (sepsis-3)[J]. JAMA, 2016, 315(8): 762-774.
[10] JIANG J, YANG J, MEI J, et al. Head-to-head comparison of qSOFA and SIRS criteria in predicting the mortality of infected patients in the emergency department: a meta-analysis[J]. Scand J Trauma Resusc Emerg Med, 2018, 26(1): 56.
[11] BOLANAKI M, WINNING J, SLAGMAN A, et al. Biomarkers improve diagnostics of sepsis in adult patients with suspected organ dysfunction based on the quick sepsis-related organ failure assessment (qSOFA) score in the emergency department[J]. Crit Care Med, 2024, 52(6): 887-899.
[12] STANSKI N L, WONG H R. Prognostic and predictive enrichment in sepsis[J]. Nat Rev Nephrol, 2020, 16(1): 20-31.
[13] WARDI G, BRICE J, CORREIA M, et al. Demystifying lactate in the emergency department[J]. Ann Emerg Med, 2020, 75(2): 287-298.
[14] GILL A, ACKERMANN K, HUGHES C, et al. Does lactate enhance the prognostic accuracy of the quick Sequential Organ Failure Assessment for adult patients with sepsis? A systematic review[J]. BMJ Open, 2022, 12(10): e060455.
[15] 中国医疗保健国际交流促进会急诊医学分会, 中华医学会急诊医学分会, 中国医师协会急诊医师分会, 等. 中国脓毒症早期预防与阻断急诊专家共识[J]. 临床急诊杂志, 2020, 21(7): 517-529.
[16] BARICHELLO T, GENEROSO J S, SINGER M, et al. Biomarkers for sepsis: more than just fever and leukocytosis-a narrative review[J]. Crit Care, 2022, 26(1): 14.
[17] PIERRAKOS C, VELISSARIS D, BISDORFF M, et al. Biomarkers of sepsis: time for a reappraisal[J]. Crit Care, 2020, 24(1): 287.
[18] CHRIST-CRAIN M, MÜLLER B. Biomarkers in respiratory tract infections: diagnostic guides to antibiotic prescription, prognostic markers and mediators[J]. Eur Respir J, 2007, 30(3): 556-573.
[19] MASJEDI A, HAJIZADEH F, BEIGI DARGANI F, et al. Oncostatin M:a mysterious cytokine in cancers[J]. Int Immunopharmacol, 2021, 90: 107158.
[20] STAWSKI L, TROJANOWSKA M. Oncostatin M and its role in fibrosis[J]. Connect Tissue Res, 2019, 60(1): 40-49.
[21] SALIM S Y, ALMALKI N, MACALA K F, et al. Oncostatin M receptor type II knockout mitigates inflammation and improves survival from sepsis in mice[J]. Biomedicines, 2023, 11(2): 483.
[22] GONG Y, YAN X, SUN X, et al. Oncostatin M is a prognostic biomarker and inflammatory mediator for sepsis[J]. J Infect Dis, 2020, 221(12): 1989-1998.
[23] 樊柳汝, 张丽中, 李金兰, 等. 脓毒症患者血清抑癌蛋白M的表达及其在脓毒症早期识别中的作用[J]. 中国呼吸与危重监护杂志, 2022, 21(6): 412-416.
[24] 王惠文, 邢柏. 国家早期预警评分联合肾上腺髓质中段肽及降钙素原对脓毒症患者预后的预测价值研究[J]. 中国全科医学, 2020, 23(21): 2647-2652.
[25] ANDRÉS C, ANDALUZ-OJEDA D, CICUENDEZ R, et al. MR-proADM to detect specific types of organ failure in infection[J]. Eur J Clin Invest, 2020, 50(6): e13246.
[26] ÖNAL U, VALENZUELA-SÁNCHEZ F, VANDANA K E, et al. Mid-regional pro-adrenomedullin (MR-proADM) as a biomarker for sepsis and septic shock: narrative review[J]. Healthcare, 2018, 6(3): 110.
[27] PORTA C, HOUSHMAND H, POVERO M, et al. Benefits of MR-proADM-guided decision-making in the emergency department: clinical and economic evaluation in Italy, Germany, Spain, and the UK[J]. J Med Econ, 2023, 26(1): 826-834.
[28] TEZZE C, ROMANELLO V, DESBATS M A, et al. Age-associated loss of OPA1 in muscle impacts muscle mass, metabolic homeostasis, systemic inflammation, and epithelial senescence[J]. Cell Metab, 2017, 25(6): 1374-1389.e6.
[29] LI X, SHEN H, ZHOU T, et al. Does an increase in serum FGF21 level predict 28-day mortality of critical patients with sepsis and ARDS?[J]. Respir Res, 2021, 22(1): 182.
[30] ZHU J, JIN Z, WANG J, et al. FGF21 ameliorates septic liver injury by restraining proinflammatory macrophages activation through the autophagy/HIF-1α axis[J]. J Adv Res, 2025, 69: 477-494.
[31] LUKIĆ I, MIHIĆ D, VARŽIĆ S C, et al. Septic cardiomyopathy[J].Rev Cardiovasc Med, 2024, 25(1):23.
[32] MAKIDE K, UWAMIZU A, SHINJO Y, et al. Novel lysophosphoplipid receptors: their structure and function[J]. J Lipid Res, 2014, 55(10): 1986-1995.
[33] WANG J, HU Y, KUANG Z, et al.GPR174 mRNA acts as a novel prognostic biomarker for patients with sepsis via regulating the inflammatory response[J]. Front Immunol, 2022, 12: 789141.
[34] WANG Q, FENG Q, ZHANG Y, et al. Decreased microRNA 103 and microRNA 107 predict increased risks of acute respiratory distress syndrome and 28-day mortality in sepsis patients[J]. Medicine, 2020, 99(25): e20729.
[35] AZIM A. Presepsin: a promising biomarker for sepsis[J]. Indian J Crit Care Med, 2021, 25(2): 117-118.
[36] PIRRACCHIO R, COHEN M J, MALENICA I, et al. Big data and targeted machine learning in action to assist medical decision in the ICU[J]. Anaesth Crit Care Pain Med, 2019, 38(4): 377-384.
[37] 魏义, 任红旗, 许娜, 等. 前列地尔联合连续性血液净化对老年急性肾衰竭病人肾功能、肾血流及炎症因子的影响[J]. 实用老年医学, 2020, 34(11): 1170-1173.
[38] SCHUETZ P, WIRZ Y, SAGER R, et al. Effect of procalcitonin-guided antibiotic treatment on mortality in acute respiratory infections: a patient level meta-analysis[J]. Lancet Infect Dis, 2018, 18(1): 95-107.